title: Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
abstract: 2,3-Diaminophenazine 1 was used as a precursor for the preparation of some novel phenazine derivatives such as imidazo[4,5-b]phenazine-2-thione 2, its methylthio 3, ethyl 1-aryl-3H-[1,2,4]triazolo[2,3-a]imidazo[4,5-b]phenazines 8a-c, ethyl (2Z)-[3-aminophenazin-2-yl)amino](phenylhydrazono)ethanoate 9, pyrazino[2,3-b]phenazine derivatives 10, 12, 15-17, [1,4]diazepino[2,3-b]phenazine derivatives 13, 14, 2,3-dibenzoylaminophenazine 18, 1H-Imidazo[4,5-b]phenazine derivatives 20, 23a-c, 24, 25 and 4-[(E)-(3-amino phenazin-2-yl)diazenyl] derivatives 27-29. All compounds were tested as inhibitors of the proliferation of human lung carcinoma and colorectal cancer cell lines through inhibition of Tyrosine Kinases. Most of compounds exert good activity against the two cancer cell lines. Five compounds (1, 2, 3, 25 and 28) were found to possess the same activity as the standard drug Cisplatin.
authors.affiliation: Photochemistry Department, National Research Center, Dokki, Giza, Egypt. Electronic address: dr_asma_chem@yahoo.com.
authors.forename: Asma M
authors.initials: AM
authors.lastname: Mahran
authors.affiliation: Photochemistry Department, National Research Center, Dokki, Giza, Egypt.
authors.forename: Sherif Sh
authors.initials: SSh
authors.lastname: Ragab
authors.affiliation: Department of Chemistry, Faculty of Science, Ain Shams University, Egypt.
authors.forename: Ahmed I
authors.initials: AI
authors.lastname: Hashem
authors.affiliation: Biochemistry Department, Division of Genetic Engineering and Biotechnology, National Research Centre, Dokki, Giza, Egypt.
authors.forename: Mamdouh M
authors.initials: MM
authors.lastname: Ali
authors.affiliation: Photochemistry Department, National Research Center, Dokki, Giza, Egypt.
authors.forename: Afaf A
authors.initials: AA
authors.lastname: Nada
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D045325:HCT116 Cells; D006571:Heterocyclic Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D015394:Molecular Structure; D010619:Phenazines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D006571:Heterocyclic Compounds; D010619:Phenazines; D047428:Protein Kinase Inhibitors; C054312:2,3-diaminophenazine; D011505:Protein-Tyrosine Kinases; D002945:Cisplatin
keywords: Antiproliferative; Azo; Diazepine; Imidazole; Phenazine; Pyrazine